{
    "clinical_study": {
        "@rank": "102698", 
        "arm_group": [
            {
                "arm_group_label": "20mg dexamethasone group", 
                "arm_group_type": "Experimental", 
                "description": "Dexamethasone 20 mg per day, 4 consecutive days"
            }, 
            {
                "arm_group_label": "40mg dexamethasone group", 
                "arm_group_type": "Experimental", 
                "description": "Dexamethasone 40 mg per day, 4 consecutive days"
            }
        ], 
        "brief_summary": {
            "textblock": "The project was undertaking by Qilu Hospital of Shandong University and other 7 well-known\n      hospitals in China. In order to report the efficacy and safety of different dose\n      dexamethasone in treating  the immune thrombocytopenia (ITP)."
        }, 
        "brief_title": "An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Immune Thrombocytopenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "detailed_description": {
            "textblock": "The investigators are undertaking a parallel group, multicentre, randomised controlled trial\n      of 60 adults with ITP from 7 medical centers in China. Part of the participants are randomly\n      selected to receive dexamethasone (given at a dose of 40mg per day for 4 consecutive days)\n      ,the others are selected to receive dexamethasone(given at a dose of 20 mg daily for 4\n      days).\n\n      Platelet count, bleeding and other symptoms were evaluated before and after treatment.\n      Adverse events are also recorded throughout the study. In order to report the efficacy and\n      safety of different dose dexamethasone for the treatment of adults with immune\n      thrombocytopenia (ITP)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Meet the diagnostic criteria for immune thrombocytopenia\n\n          2. Untreated hospitalized patients, may be male or female, between the ages of 18 ~ 75\n             years\n\n          3. To show a platelet count <30 * 10^9/L, and with bleeding manifestations\n\n          4. Willing and able to sign written informed consent\n\n        Exclusion Criteria:\n\n          1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts\n             within 3 months before the screening visit\n\n          2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine,\n             vincristine, vinblastine, etc) within 3 months before the screening visit\n\n          3. Received high-dose steroids or IVIG in the 3 weeks prior to the start of the study\n\n          4. Current HIV infection or hepatitis B virus or hepatitis C virus infections\n\n          5. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP\n             Unstable or uncontrolled disease or condition related to or impacting cardiac\n             function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension\n             or cardiac arrhythmia)\n\n          6. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate\n             pregnancy during the study period\n\n          7. Have a known diagnosis of other autoimmune diseases, established in the medical\n             history and laboratory findings with positive results for the determination of\n             antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct\n             Coombs test\n\n          8. Patients who are deemed unsuitable for the study by the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153060", 
            "org_study_id": "ITP-Dexamethasone"
        }, 
        "intervention": [
            {
                "arm_group_label": "40mg dexamethasone group", 
                "description": "Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "Dexamethasone"
            }, 
            {
                "arm_group_label": "20mg dexamethasone group", 
                "description": "Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "Dexamethasone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "immune thrombocytopenia", 
            "dexamethasone", 
            "efficacy", 
            "safety"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "houming@medmail.com.cn", 
                "last_name": "Ming Hou, Dr.", 
                "phone": "+86-531-82169114", 
                "phone_ext": "9879"
            }, 
            "facility": {
                "address": {
                    "city": "Jinan", 
                    "country": "China", 
                    "state": "Shandong", 
                    "zip": "250012"
                }, 
                "name": "Qilu Hospital, Shandong University"
            }, 
            "investigator": {
                "last_name": "Ming Hou, Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Different Doses of Dexamethasone for Management of Immune Thrombocytopenia (ITP)", 
        "overall_contact": {
            "email": "houming@medmail.com.cn", 
            "last_name": "Ming Hou, DR.", 
            "phone": "+86-531-82169114", 
            "phone_ext": "9879"
        }, 
        "overall_contact_backup": {
            "email": "junpeng88@sina.com.cn", 
            "last_name": "Jun Peng, DR.", 
            "phone": "+86-531-82169114", 
            "phone_ext": "9867"
        }, 
        "overall_official": {
            "affiliation": "Shandong University", 
            "last_name": "Ming Hou, DR.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Complete response (CR)\uff1a A platelet count \u2265 100 * 10^9/L measured on two occasions > 7 days apart and the absence of bleeding.\nResponse (R)\uff1a A platelet count \u2265 30 * 10^9/L and a greater than two fold increase in platelet count from baseline measured on two occasions > 7 days apart and the absence of bleeding.\nNo response (NR)\uff1a A platelet count < 30 * 10^9/L or a less than two fold increase in platelet count from baseline or the presence of bleeding. Platelet count must be measured on two occasions more than a day apart.", 
            "measure": "Proposed criteria for assessing early response to ITP treatments", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "reference": [
            {
                "PMID": "19005182", 
                "citation": "Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, K\u00fchne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386-93. Epub 2008 Nov 12."
            }, 
            {
                "PMID": "19846889", 
                "citation": "Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. Epub 2009 Oct 21. Review."
            }, 
            {
                "PMID": "12944568", 
                "citation": "Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003 Aug 28;349(9):831-6."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153060"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shandong University", 
            "investigator_full_name": "Ming Hou", 
            "investigator_title": "Professor and Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The type and frequency of therapy associated adverse events", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "1 years"
        }, 
        "source": "Shandong University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Chinese Academy of Medical Sciences", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shandong Provincial Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The First Affiliated Hospital of Dalian Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Peking Union Medical College Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shandong University of Traditional Chinese Medicine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Anhui Provincial Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Second Affiliated Hospital of Shanxi Medical University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Shandong University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}